Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.

Natalia MaximovaAlessandra MaestroDavide ZanonAnnalisa Marcuzzi

Published in: Journal for immunotherapy of cancer (2020)

Anti-IL-6 and anti-TNF-α target treatment of very severe AEs may afford an immediate resolution of potentially life-threatening symptoms and reduce the duration and the costs of hospitalization. Maintenance of therapeutic infliximab blood concentrations permits an early switch to dabrafenib after vemurafenib-related AEs.

Keyphrases

drug induced
rheumatoid arthritis
ulcerative colitis
sleep quality
high glucose
diabetic rats
emergency department
case report
juvenile idiopathic arthritis
single molecule
systemic lupus erythematosus
loop mediated isothermal amplification
quantum dots
replacement therapy